Previsão

Comprar	1
Manter	0
Vender	0

Notícias Ir para o feed de notícias

Almirall raises EBITDA sharply; biologics sales drive growth

Almirall reports H1 2026 EBITDA of €150.7 million (+23.7%) and net sales of €602.7 million (+7.5%), largely meeting or exceeding expectations. The growth was driven mainly by biologics: Ebglyss reached €84.5 million in sales (+88.2%) and Ilumetri €125.2 million (+10.5%), while the dermatology business in Europe grew by 18.1%. Management confirms the full-year guidance (net sales +9–12%, EBITDA €270–290 million); net income of €39.6 million was slightly below consensus and Ebglyss’s growth slowed in Q2, which dampened the share price recovery. » Mais em de.investing.com
Almirall reports mixed Q1 results: net revenue slightly below forecast, EBITDA beats

Almirall reported Q1 net revenue of €291.0m (consensus €293.4m) and total revenues of €292.4m, slightly below expectations. Profitability was robust: EBITDA €67.5m (consensus €66.7m), EBIT €30.0m (consensus €29.3m), while net profit of €15.3m missed the consensus of €19.1m, weighed down by higher net financial expenses and a revaluation of an equity swap. The dermatology business grew 16.3% to €179.7m, driven by Ebglyss (€41.9m) and Ilumetri (€61.6m). Almirall confirmed its full-year outlook (net revenue €1,208–1,241m, EBITDA €270–290m) and reported a bispecific antibody candidate entering Phase I studies. » Mais em de.investing.com
Almirall achieves over €1.1bn revenue in 2025 for first time thanks to biologics

Almirall reports net sales of €1,108.1m for fiscal 2025 (+12.4%) and an EBITDA of €232.9m, driven by strong sales of the biologics Ilumetri and Ebglyss in Europe. Ilumetri generated €234.4m, Ebglyss grew to €110.8m, while the US business suffered from competitive pressure and negative currency effects. For 2026 management expects revenue growth of 9–12% and an EBITDA of €270–290m; medium-term, Almirall aims for a double-digit CAGR through 2030 and an EBITDA margin around 25%. The balance sheet remains solid with a net leverage of 0.0x, but the stock fell about 1.56% after the announcement. » Mais em de.investing.com

Dividendos históricos Dividendos

Todos os indicadores de dividendos Todos os indicadores

Em 2026, ALMIRALL já distribuiu € 0,19 em dividendos. A última distribuição ocorreu em maio.

Dados financeiros da empresa

No último trimestre, ALMIRALL registou receitas de € 310,32 mi e um ganho líquido de € 24,3 mi

(EUR)	junho de 2026	YoY
Receitas	310,32 mi	13,11%
Ganho bruto	574,44 mi	129,92%
Ganho líquido	24,3 mi	388,05%
EBITDA	77,72 mi	44,75%

Dados fundamentais

Métrica	Valor
Capitalização bolsista	€ 2,23 bi
Número de ações	217,78 mi
Máximo/mínimo de 52 semanas	€ 13,98 - € 10,02
Rentabilidade de dividendos	1,85%
Dividendos TTM	€ 0,19
Beta	0,17
PER (PE Ratio)	30,91
PEG (PEG Ratio)	0,13
P/VC (PB Ratio)	1,46
P/V (PS Ratio)	1,58

Perfil da empresa

Almirall, S.A., ein biopharmazeutisches Unternehmen, beschäftigt sich mit der Erforschung, Entwicklung, Herstellung und dem Verkauf von Medikamenten für die Hautgesundheit in Europa, den Vereinigten Staaten und international. Das Unternehmen bietet seine Produkte für dermatologische Erkrankungen wie aktinische Keratose, atopische Dermatitis, androgene Alopezie, Psoriasis, Onychomykose, Onkodermatologie, Akne und seltene Indikationen sowie für das Herz-Kreislauf-System, den Bewegungsapparat, die Atemwege und das Nervensystem, den Verdauungstrakt und den Stoffwechsel, Antiinfektiva zur systemischen Anwendung, das Urogenitalsystem und Sexualhormone, Immunstimulanzien und systematische Hormonpräparate an. Zu seinen Produkten gehören Ilumetri, Solaraze, Actikerall, Ciclopoli, Skilarence, Aczone, Decoderm, Cordran Tape, Azelex, Klisyri, Tazorac, Seysara, Veltin, Almax, Ebastel, Sativex, Crestor und Efficib/Tesavel. Almirall, S.A. hat Kooperations- und Partnerschaftsvereinbarungen mit Tyris Therapeutics, BIOMAP, der Universität Dundee, Kaken Pharmaceutical Co Ltd, Ichnos Sciences Inc, der Universität Carlos III Madrid und der MEDINA Foundation, 23andMe, Inc, HitGen Ltd, WuXi Biologics, Eli Lilly and Company, und Athenex, Inc. Das Unternehmen war früher unter dem Namen Laboratorios Almirall, S.A. bekannt und änderte im Mai 2009 seinen Namen in Almirall, S.A.. Almirall, S.A. wurde 1943 gegründet und hat seinen Hauptsitz in Barcelona, Spanien.

Nome	ALMIRALL
CEO	Carlos Gallardo Piqué
Sede	Barcelona, ct Espanha
Site	almirall.com
Setor	Cuidados de saúde
Indústria	Produtos farmacêuticos
Entrada em bolsa	20/06/2007
Colaboradores	2.097